Siga Technologies, a biotech firm that employs about 50 in Corvallis, is appealing a federal decision that could cost the company billions.
Last month Siga was awarded a contract by the Biomedical Advanced Research and Development Authority, an arm of the Department of Health and Human Services, to produce 1.7 million courses of a novel smallpox drug for the Strategic National Stockpile. The $500 million contract, awarded under a small-business set-aside program, included provisions that could escalate the value of the deal to $2.8 billion.
Rival bidder Chimerix Inc. appealed the award to the Small Business Administration on the grounds that Siga was too big to qualify for the small-business set-aside. On Friday, an SBA official upheld that appeal.
Now Siga has announced plans to appeal that ruling in hopes of salvaging the BARDA contract.
Read more at the Gazette-Times.
Latest from Oregon Business Team
- The 2023 100 Best Companies to Work for in Oregon survey is open!
- New for the 2023 Survey: Customized, Supplemental 100 Best Survey Questions
- Fresh Solutions for Flexible Workplaces
- Hop In! How Shared Rides Boost Staff Benefits
- Recruit, retain employees + create thriving workplaces by leveraging low-cost commute benefits